Our clinical results together with a plausible pathogenic mechanism suggest that circulating anti-Gal-8 antibodies might be an early prognostic maker in RRMS and prompt to consider a therapeutic use of this lectin in patients bearing anti-Gal-8 antibodies. The gene discussed is LGALS8; the disease is relapsing-remitting multiple sclerosis.